Trials / Recruiting
RecruitingNCT06888193
A Study to Assess the Concentration of Bimekizumab in Mature Breast Milk From Mothers Receiving Treatment With Bimzelx® (Bimekizumab)
A Multicenter Open-label, Prospective Study to Assess the Concentration of Bimekizumab in Mature Breast Milk From Mothers Receiving Treatment With Bimzelx® (Bimekizumab)
- Status
- Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 20 (estimated)
- Sponsor
- UCB Biopharma SRL · Industry
- Sex
- Female
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Primary purpose of the study is to assess the concentration of bimekizumab in mature human breast milk.
Conditions
- Moderate to Severe Plaque Psoriasis
- Psoriatic Arthritis
- Axial Spondyloarthritis
- Hidradenitis Suppurativa
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Bimekizumab | Bimekizumab under the care of their treating physician. |
Timeline
- Start date
- 2025-11-05
- Primary completion
- 2027-05-03
- Completion
- 2027-05-03
- First posted
- 2025-03-21
- Last updated
- 2026-04-03
Locations
11 sites across 5 countries: United States, Canada, Germany, Spain, Switzerland
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06888193. Inclusion in this directory is not an endorsement.